| dbo:abstract |
Bucinnazine (AP-237, 1-butyryl-4-cinnamylpiperazine) is an opioid analgesic drug that was widely used in China to treat pain in cancer patients as of 1986. It is one of the most potent compounds among a series of piperazine-amides first synthesized and reported in Japan in the 1970s. Bucinnazine has analgesic potency comparable to that of morphine but with a relatively higher therapeutic index. The drug was initially claimed to be a non-narcotic analgesic. However, subsequent studies have shown bucinnazine and similar acyl piperazines to be potent and selective agonists of μ-opioid receptor (MOR) with relatively low affinity for the δ-opioid receptor and the κ-opioid receptor. In accordance with these studies, results from the intravenous self-administration experiments in rats showed that bucinnazine has a marked reinforcing effect with tolerance and dependence quickly developing. In addition, the morphine antagonist naloxone reverses the effect of bucinnazine and precipitates withdrawal symptoms in bucinnazine treated rats further indicating a mechanism of analgesia mediated via selective agonist activity at μ-opioid receptors. (en) |
| dbo:casNumber |
17719-89-0 17730-82-4 (HCl) |
| dbo:fdaUniiCode |
J735KL8O54 |
| dbo:pubchem |
6005081 |
| dbo:thumbnail |
wiki-commons:Special:FilePath/AP-237.svg?width=300 |
| dbo:wikiPageExternalLink |
https://pubchem.ncbi.nlm.nih.gov/compound/6447698 |
| dbo:wikiPageID |
52244085 (xsd:integer) |
| dbo:wikiPageLength |
5933 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1102179564 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Cancer dbr:Designer_drug dbr:Δ-opioid_receptor dbc:Analgesics dbc:Mu-opioid_receptor_agonists dbc:Piperazines dbr:Morphine dbr:MT-45 dbr:Pain dbr:Substance_dependence dbr:Therapeutic_index dbr:Azaprocin dbr:Drug_tolerance dbr:Agonists dbr:Amide dbc:Euphoriants dbr:Hydrochloride dbr:Μ-opioid_receptor dbr:AP-238 dbc:Amides dbr:Sunifiram dbr:Diphenpipenol dbr:Opioid dbr:Κ-opioid_receptor dbr:Withdrawal_symptoms dbr:File:2-Methyl-AP-237_structure.png |
| dbp:c |
17 (xsd:integer) |
| dbp:casNumber |
17719 (xsd:integer) |
| dbp:casSupplemental |
17730 (xsd:integer) |
| dbp:chemspiderid |
4777510 (xsd:integer) |
| dbp:h |
24 (xsd:integer) |
| dbp:iupacName |
1 (xsd:integer) |
| dbp:legalUk |
PSA (en) |
| dbp:n |
2 (xsd:integer) |
| dbp:o |
1 (xsd:integer) |
| dbp:pubchem |
6005081 (xsd:integer) |
| dbp:smiles |
CCCCN1CCNC/C=C/C2=CC=CC=C2 (en) |
| dbp:stdinchi |
1 (xsd:integer) |
| dbp:stdinchikey |
ZQBMUHABRSEAIK-UXBLZVDNSA-N (en) |
| dbp:synonyms |
AP-237 (en) |
| dbp:unii |
J735KL8O54 (en) |
| dbp:wikiPageUsesTemplate |
dbt:Drugbox dbt:Reflist dbt:Cascite dbt:Drugbankcite |
| dct:subject |
dbc:Analgesics dbc:Mu-opioid_receptor_agonists dbc:Piperazines dbc:Euphoriants dbc:Amides |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug |
| rdfs:comment |
Bucinnazine (AP-237, 1-butyryl-4-cinnamylpiperazine) is an opioid analgesic drug that was widely used in China to treat pain in cancer patients as of 1986. It is one of the most potent compounds among a series of piperazine-amides first synthesized and reported in Japan in the 1970s. Bucinnazine has analgesic potency comparable to that of morphine but with a relatively higher therapeutic index. (en) |
| rdfs:label |
Bucinnazine (en) |
| owl:sameAs |
wikidata:Bucinnazine https://global.dbpedia.org/id/2YraK |
| prov:wasDerivedFrom |
wikipedia-en:Bucinnazine?oldid=1102179564&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/2-Methyl-AP-237_structure.png wiki-commons:Special:FilePath/AP-237.svg |
| foaf:isPrimaryTopicOf |
wikipedia-en:Bucinnazine |
| is dbo:wikiPageRedirects of |
dbr:AP-237 dbr:2-Methyl-AP-237 |
| is dbo:wikiPageWikiLink of |
dbr:List_of_designer_drugs dbr:AP-237 dbr:AP-238 dbr:Acetoxymethylketobemidone dbr:Sunifiram dbr:Diphenpipenol dbr:C17H24N2O dbr:2-Methyl-AP-237 |
| is foaf:primaryTopic of |
wikipedia-en:Bucinnazine |
